Literature DB >> 14973155

Use of MGIT 960 for rapid quantitative measurement of the susceptibility of Mycobacterium tuberculosis complex to ciprofloxacin and ethionamide.

Tsi-Shu Huang1, Susan Shin-Jung Lee, Hui-Zin Tu, Wen-Kuei Huang, Yao-Shen Chen, Chung-Kai Huang, Shue-Ren Wann, Hsi-Hsun Lin, Yung-Ching Liu.   

Abstract

OBJECTIVES: Tentative standards for testing MICs for Mycobacterium tuberculosis include agar dilution and the BACTEC method. However, the conventional agar dilution method requires 3-5 weeks to complete; whereas BACTEC, although a rapid test, involves the use of radioisotopes. In contrast, the MGIT 960 system uses a fluorescence quenching based oxygen sensor that can be read automatically. This system is not only robust, safe and simple, but has been validated for susceptibility tests of first-line antituberculous agents.
METHODS: We evaluated 46 clinical strains of M. tuberculosis isolated from patients admitted to Kaohsiung Veterans General Hospital. Testing of MICs of ciprofloxacin and ethionamide was carried out by MGIT 960 and compared with the agar dilution method.
RESULTS: Good agreement was found between MGIT 960 and agar dilution. The greatest concordance between the agar dilution and MGIT assay at +/-1 and +/-2 dilution was 80.4% and 97.8% for ciprofloxacin, and 82.6% and 93.5% for ethionamide, respectively.
CONCLUSION: MGIT 960 was found to be comparable to the current NCCLS standard method, agar dilution, and has the advantage of being rapid (obtaining results within 5-17 days, average 8.9 days) and easy to achieve standardization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14973155     DOI: 10.1093/jac/dkh120

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials.

Authors:  Sabine Rüsch-Gerdes; Gaby E Pfyffer; Manuel Casal; Maureen Chadwick; Salman Siddiqi
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

2.  Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.

Authors:  Devyani Deshpande; Jotam G Pasipanodya; Stellah G Mpagama; Shashikant Srivastava; Paula Bendet; Thearith Koeuth; Pooi S Lee; Scott K Heysell; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

3.  Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis.

Authors:  Mohammad H Al-Shaer; Anne-Grete Märtson; Wael A Alghamdi; Abdullah Alsultan; Guohua An; Shahriar Ahmed; Yosra Alkabab; Sayera Banu; Eric R Houpt; David Ashkin; David E Griffith; J Peter Cegielski; Scott K Heysell; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

4.  Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation.

Authors:  Burkhard Springer; Katja Lucke; Romana Calligaris-Maibach; Claudia Ritter; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2009-04-01       Impact factor: 5.948

5.  Direct sequencing for rapid detection of multidrug resistant Mycobacterium tuberculosis strains in Morocco.

Authors:  Fathiah Zakham; Imane Chaoui; Amina Hadbae Echchaoui; Fouad Chetioui; My Driss Elmessaoudi; My Mustapha Ennaji; Mohammed Abid; Mohammed El Mzibri
Journal:  Infect Drug Resist       Date:  2013-11-28       Impact factor: 4.003

6.  Development of Human Cell-Based In Vitro Infection Models to Determine the Intracellular Survival of Mycobacterium avium.

Authors:  Gül Kilinç; Kimberley V Walburg; Kees L M C Franken; Merel L Valkenburg; Alexandra Aubry; Mariëlle C Haks; Anno Saris; Tom H M Ottenhoff
Journal:  Front Cell Infect Microbiol       Date:  2022-06-24       Impact factor: 6.073

7.  Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis.

Authors:  Hyejin Kim; Minji Seo; Young Kil Park; Jae-Il Yoo; Yeong Seon Lee; Gyung Tae Chung; Sungweon Ryoo
Journal:  Tuberc Res Treat       Date:  2013-03-28

8.  Determination of the activity of standard anti-tuberculosis drugs against intramacrophage Mycobacterium tuberculosis, in vitro: MGIT 960 as a viable alternative for BACTEC 460.

Authors:  Sarbjit Singh Jhamb; Amit Goyal; Prati Pal Singh
Journal:  Braz J Infect Dis       Date:  2014-04-04       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.